tbuckley/cabot-search huggingface dataset:
A OHCs‐Targeted Strategy for PEDF Delivery in Noise‐Induced Hearing Loss
Authors: Zeqi Zhao, Zhengzhong Han, Yudi Shao, Konduru Naveena, Jintao Yuan, Nan Zhou, Caiji Wang, Xuanyi Li, Xi Shi, Dan Jin, Bing Xu, Fuxing Dong, Zhiwei Liu, Wei Li, Hongmei Liu, Yuehua Qiao
Journal: Advanced Healthcare Materials (2025)

Abstract Noise‐induced hearing loss (NIHL) results from prolonged exposure to intense noise, causing damage to sensory outer hair cells (OHCs) and spiral ganglion neurons (SGNs). The blood labyrinth barrier (BLB) hinders systemic drug delivery to the inner ear. This study applied a retro‐auricular round window membrane (RWM) method to bypass the BLB, enabling the transport of macromolecular proteins into the inner ear. Pigment epithelium‐derived factor (PEDF), which has anti‐inflammatory and neuroprotective properties, is conjugated to a prestin‐targeting peptide 2 (PrTP2) using N‐succinimidyl‐3‐maleimidopropionate (SMP) to form PrTP2‐SMP/PEDF. This compound specifically targeted Prestin and accumulated around OHCs for sustained release, effectively reducing OHC and SGN loss. Functional and structural tests, including auditory brainstem response (ABR), confocal microscopy, and scanning electron microscopy (SEM), revealed significant hearing restoration and cellular protection. Additionally, the results of enzyme‐linked immunosorbent assay (ELISA), Annexin V and propidium iodide (PI) staining and immunoblotting show that noise exposure may induce pyroptosis in the cochlea by activating the NOD‐like receptor protein 3 (NLRP3)‐apoptosis‐associated speck‐like protein containing a CARD (ASC) – cysteinyl aspartate specific proteinase (Caspase‐1) pathway and PrTP2‐SMP/PEDF alleviates the inflammatory response by inhibiting pyroptosis. Toxicity analysis indicates no adverse effects, suggesting that PrTP2‐SMP/PEDF has a promising therapeutic prospective for NIHL.
Photocontrolled Bionic Micro‐Nano Hydrogel System used Novel Functional Strategy for Cell Delivery and Large‐Scale Corneal Repair
Authors: Mingshan Zhang, Shi‐yao Zhang, Huiqin Zhang, Youwei Liu, Yipeng Dong, Daobo Han, Le Chang, Ning Yang, Jianguo Tian, Yan Wang, Qing Ye
Journal: Advanced Healthcare Materials (2025)

Abstract Reproducing the microstructure of the natural cornea remains a significant challenge in achieving the mechanical and biological functionality of artificial corneas. Therefore, the development of cascade structures that mimic the natural extracellular matrix (ECM), achieving both macro‐stability and micro‐structure, is of critical importance. This study proposes a novel, efficient, and general photo‐functionalization strategy for modifying natural biomaterials. Collagen microfibers obtained through electrospinning are functionalized with an active N‐Hydroxysuccinimide (NHS) ester, to impart light‐curing ability. This approach expands the construction of photo‐controllable hydrogel systems beyond conventional single methacrylate (MA) modifications or di‐tyrosine bonding, enabling integration with other biomaterials for comprehensive ECM remodeling. Subsequently, the collagen microfibers are then photo‐embedded into gelatin methacryloyl (GelMA) via covalent crosslinking to form a fibrous hydrogel, which supports both structural and functional requirements. In terms of biological functionality, the hydrogel promotes significant inward migration and retention of human corneal fibroblasts (hCFs), replicating ECM‐like environments. Furthermore, its excellent burst resistance suggests potential as a bioadhesive. In a rabbit model, the hydrogel achieved effective repair of large‐sized (6 mm) corneal defects, facilitates epithelial migration, and maintained long‐term stability. This work provides valuable guidance for designing efficient and simplified bioactive materials for corneal repair and broader tissue engineering applications.
A systematic review of passive data for remote monitoring in psychosis and schizophrenia
Authors: Siân Bladon, Emily Eisner, Sandra Bucci, Anuoluwapo Oluwatayo, Glen P. Martin, Matthew Sperrin, John Ainsworth, Sophie Faulkner
Journal: npj Digital Medicine (2025)

Abstract There is increasing use of digital tools to monitor people with psychosis and schizophrenia remotely, but using this type of data is challenging. This systematic review aimed to summarise how studies processed and analysed data collected through digital devices. In total, 203 articles collecting passive data through smartphones or wearable devices, from participants with psychosis or schizophrenia were included in the review. Accelerometers were the most common device ( n = 115 studies), followed by smartphones ( n = 46). The most commonly derived features were sleep duration ( n = 50) and time spent sedentary ( n = 41). Thirty studies assessed data quality and another 69 applied data quantity thresholds. Mixed effects models were used in 21 studies and time-series and machine-learning methods were used in 18 studies. Reporting of methods to process and analyse data was inconsistent, highlighting a need to improve the standardisation of methods and reporting in this area of research.
AI driven decision support reduces antibiotic mismatches and inappropriate use in outpatient urinary tract infections
Authors: Shirley Shapiro Ben David, Roni Romano, Daniella Rahamim-Cohen, Joseph Azuri, Shira Greenfeld, Ben Gedassi, Uri Lerner
Journal: npj Digital Medicine (2025)

Urinary tract infections (UTIs) often prompt empiric outpatient antibiotic prescriptions, risking mismatches. This study evaluates the impact of "UTI Smart-Set" (UTIS), an AI-driven decision-support tool, on prescribing patterns and mismatches in a large outpatient organization. UTIS integrates machine learning forecasts of antibiotic resistance, patient data, and guidelines into a user-friendly order set for UTI management. From 6/1/2021–8/31/2022, 171,010 UTI diagnoses were recorded, with UTIS used in 75,630 cases involving antibiotic prescriptions. Overall acceptance rate of UTIS recommendations was 66.0%. Among 19,287 cases with urine cultures, antibiotic mismatch rate was significantly lower when UTIS recommendations were followed (8.9% vs. 14.2%, p < 0.0001). Among women over 18, mismatch rate was 47.5% lower, and among women over 50, 55.6% lower (p < 0.001). Additionally, an overall reduction of 80.5% in ciprofloxacin usage (6.4% vs 32.9%, p < 0.0001) was observed. UTIS improved prescribing accuracy, reduced mismatches, and minimized quinolone use, highlighting AI's potential for personalized infection management.
Mucus-penetrating microbiota drive chronic low-grade intestinal inflammation and metabolic dysregulation
Authors: Melissa C. Kordahi, Noëmie Daniel, Andrew T. Gewirtz, Benoit Chassaing
Journal: Gut Microbes (2025)

Metabolic syndrome is, in humans, associated with alterations in the composition and localization of the intestinal microbiota, including encroachment of bacteria within the colon's inner mucus layer. Possible promoters of these events include dietary emulsifiers, such as carboxymethylcellulose (CMC) and polysorbate-80 (P80), which, in mice, result in altered microbiota composition, encroachment, low-grade inflammation and metabolic syndrome. While assessments of gut microbiota composition have largely focused on fecal/luminal samples, we hypothesize an outsized role for changes in mucus microbiota in driving low-grade inflammation and its consequences. In support of this notion, we herein report that both CMC and P80 led to stark changes in the mucus microbiome, markedly distinct from those observed in feces. Moreover, transfer of mucus microbiota from CMC- and P80-fed mice to germfree mice resulted in microbiota encroachment, low-grade inflammation, and various features of metabolic syndrome. Thus, we conclude that mucus-associated bacteria are pivotal determinants of intestinal inflammatory tone and host metabolism.
A scoping review of privacy and utility metrics in medical synthetic data
Authors: Bayrem Kaabachi, Jérémie Despraz, Thierry Meurers, Karen Otte, Mehmed Halilovic, Bogdan Kulynych, Fabian Prasser, Jean Louis Raisaro
Journal: npj Digital Medicine (2025)

The use of synthetic data is a promising solution to facilitate the sharing and reuse of health-related data beyond its initial collection while addressing privacy concerns. However, there is still no consensus on a standardized approach for systematically evaluating the privacy and utility of synthetic data, impeding its broader adoption. In this work, we present a comprehensive review and systematization of current methods for evaluating synthetic health-related data, focusing on both privacy and utility aspects. Our findings suggest that there are a variety of methods for assessing the utility of synthetic data, but no consensus on which method is optimal in which scenario. Moreover, we found that most studies included in this review do not evaluate the privacy protection provided by synthetic data, and those that do often significantly underestimate the risks.
FSH exacerbates bone loss by promoting osteoclast energy metabolism through the CREB-MDH2-NAD+ axis
Authors: Jingqiu Chen, Yilin Liao, Yue Sheng, Hantao Yao, Ting Li, Zhenru He, Weng Wan Yue Ye, Mengjie Yin, Huilin Tang, Yaoyu Zhao, Peiqi Zhang, Yuting Wang, Xiazhou Fu, Yaoting Ji
Journal: Metabolism (2025)
Genotype-phenotype correlation for skin and neuropsychiatric features in tuberous sclerosis complex
Authors: Emi Kaneda, Hanako Koguchi-Yoshioka, Keisuke Nimura, Satoshi Hattori, Saki Ishino, Manabu Fujimoto, Mari Wataya-Kaneda
Journal: British Journal of Dermatology (2025)

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by pathogenic variants in the TSC1 and TSC2 genes. This condition manifests as diverse symptoms across multiple organ systems and is frequently associated with neuropsychiatric symptoms. However, the relationship between the severity of these manifestations remains poorly understood. This study aimed to elucidate correlations between the severity of various skin and neuropsychiatric symptoms and the underlying TSC1/TSC2 gene pathology.
Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report
Authors: Timothy E Dribin, Antonella Muraro, Carlos A Camargo, Paul J Turner, Julie Wang, Graham Roberts, Aikaterini Anagnostou, Susanne Halken, Jay Liebermann, Margitta Worm, Torsten Zuberbier, Hugh A Sampson
Journal: Journal of Allergy and Clinical Immunology (2025)
Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study
Authors: Tara T M Lee, Corinne Collett, Simon Bergford, Sara Hartnell, Eleanor M Scott, Robert S Lindsay, Katharine F Hunt, David R McCance, Rebecca M Reynolds, Malgorzata E Wilinska, Judy Sibayan, Craig Kollman, Roman Hovorka, Helen R Murphy
Journal: The Lancet Diabetes & Endocrinology (2025)
Health Expenditures of Patients With Diabetes After Bariatric Surgery: Comparing Gastric Bypass and Sleeve Gastrectomy
Authors: Matthew L. Maciejewski, Lindsay Zepel, Valerie A. Smith, David E. Arterburn, Mary K. Theis, Aileen Baecker, Caroline Sloan, Amy G. Clark, Ryan M. Kane, Christopher R. Daigle, Karen J. Coleman, Aniket A. Kawatkar
Journal: Annals of Internal Medicine (2025)

Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) differ in their effects on body weight and risk for reoperation. However, it is unclear whether long-term health expenditures differ by procedure type in patients with diabetes. To compare health expenditures 3 years before and 5.5 years after bariatric surgery between patients with diabetes undergoing RYGB versus SG. Retrospective cohort study using target trial emulation principles. Integrated health system. Patients with diabetes undergoing RYGB (n = 3147) or SG (n = 3510) from 2012 to 2019. Total, inpatient, outpatient, and medication expenditures. Characteristics of patients undergoing RYGB and SG were well balanced after weighting; 73% were female, average body mass index was 43.8 kg/m2, and average age was 50 years. Expenditures per 6-month period decreased by about 30% for both groups, from $4039.06 (95% CI, $3770.88 to $4326.31) 3 years before to $2441.13 (CI, $2151.07 to $2770.30) 5.5 years after RYGB and from $3918.37 (CI, $3658.75 to $4196.40) 3 years before to $2658.15 (CI, $2279.17 to $3100.16) 5.5 years after SG. Total expenditures after surgery did not differ between groups through 5.5 years (difference at 5.5 years, -$217.02 [CI, -$671.29 to $201.96]) except for the first 6 months, when expenditures were transiently higher in the RYGB group (difference, $564.32 [CI, $232.60 to $895.20]), driven by a higher inpatient admission rate. Otherwise, postsurgical outpatient and medication expenditures did not appear to differ between RYGB and SG. Unobserved confounding. Overall expenditures decreased substantially in the postsurgical period, primarily due to reductions in pharmacy expenditures, with no differences between RYGB and SG except in the first 6 months after surgery. National Institute of Diabetes and Digestive and Kidney Diseases.
The Association of Epstein–Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation
Authors: Vishnu S. Potluri, Siqi Zhang, Douglas E. Schaubel, Salma Shaikhouni, Emily A. Blumberg, Sunita D. Nasta, Roy D. Bloom, Massiel Cruz-Peralta, Rajil B. Mehta, Nikhil R. Lavu, Bereket Getachew, Srijan Tandukar, Peter P. Reese, Chethan M. Puttarajappa
Journal: Annals of Internal Medicine (2025)

Prior studies indicate that 1% to 4% of Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R-) kidneys develop posttransplant lymphoproliferative disorder (PTLD). However, these estimates are based on limited data that lack granularity. To determine the associations between pretransplant EBV D+/R- and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival among adult kidney transplant recipients. Retrospective cohort study. Two large U.S. transplant centers. Epstein-Barr virus D+/R- and EBV R+ recipients matched 1:3 on donor, recipient, and transplant characteristics between 1 January 2010 and 30 June 2022. Exposure was pretransplant donor and recipient EBV serostatus. The primary outcome was biopsy-proven PTLD. Secondary outcomes were all-cause graft loss (death, retransplant, or graft failure) and death. Follow-up was truncated to 3 years after transplant. The final cohort comprised 104 EBV D+/R- recipients matched to 312 EBV R+ recipients. The mean age was 42 years (SD, 17.1), 59% were living donor transplants, and 95% received thymoglobulin induction. Among EBV D+/R- recipients, 50 (48.1%) developed EBV DNAemia, with a median time of 198 days (IQR, 110 to 282 days) after transplantation. Posttransplant lymphoproliferative disorder occurred in 23 (22.1%) EBV D+/R- recipients at a median of 202 days (IQR, 118 to 317 days) after transplantation. Epstein-Barr virus D+/R- recipients had higher all-cause graft failure (hazard ratio, 2.21 [95% CI, 1.06 to 4.63]); mortality was higher but not statistically significant (hazard ratio, 2.19 [CI, 0.94 to 5.13]). Two-center study. Compared with previous studies, this study showed that EBV D+/R- kidney recipients face a 5- to 10-fold higher cumulative incidence of PTLD. Strategies to mitigate the PTLD risk are urgently needed. National Institutes of Health.
Guidelines International Network: Principles for Use of Artificial Intelligence in the Health Guideline Enterprise
Authors: Bernardo Sousa-Pinto, Manuel Marques-Cruz, Ignacio Neumann, Yuan Chi, Artur J. Nowak, Marge Reinap, Mariette Awad, Monika Nothacker, Milana Trucl, Jan Brozek, Pablo Alonso-Coello, Wojtek Wiercioch, Amir Qaseem, Elie A. Akl, Holger J. Schünemann, Zachary Munn, Lubna El-Ansary, Ina Kopp, Miranda Langendam, Roberta James, Murad Alam
Journal: Annals of Internal Medicine (2025)

Artificial intelligence (AI) has been defined by the High-Level Expert Group on AI of the European Commission as "systems that display intelligent behaviour by analysing their environment and taking actions-with some degree of autonomy-to achieve specific goals." Artificial intelligence has the potential to support guideline planning, development and adaptation, reporting, implementation, impact evaluation, certification, and appraisal of recommendations, which we will refer to as "guideline enterprise." Considering this potential, as well as the lack of guidance for the use of AI in guidelines, the Guidelines International Network (GIN) proposes a set of principles for the development and use of AI tools or processes to support the health guideline enterprise. A GIN working group on AI developed these principles, informed by the results of a scoping review and practical examples, through iterative discussion. Eight principles were identified to adhere to when using AI in the guideline context: transparency, preplanning, additionality, credibility, ethics, accountability, compliance, and evaluation. These complementary principles are described in a comprehensive way, but they do not provide detailed instructions on how to use specific AI tools. Although these principles are expected to apply across different contexts and stages of the guideline enterprise, details on their implementation have some degree of flexibility. Guideline development groups choosing to use AI will be able to adequately implement the principles if they ensure aspects such as structured reporting on the use of AI tools, involvement of experts in AI, and allocation of funding for the adequate use of AI tools. The GIN principles may support guideline developers in the responsible and transparent use of AI to ensure trustworthy guidelines.
Effects of Noise and Public Setting on Blood Pressure Readings
Authors: Junichi Ishigami, Hairong Liu, Di Zhao, Ahmed Sabit, Chathurangi H. Pathiravasan, Jeanne Charleston, Edgar R. Miller, Kunihiro Matsushita, Lawrence J. Appel, Tammy M. Brady
Journal: Annals of Internal Medicine (2025)

Guidelines emphasize quiet settings for blood pressure (BP) measurement.
ACP Updates Family and Medical Leave Policy
Authors: Renee Butkus
Journal: Annals of Internal Medicine (2025)

TO THE EDITOR: Relevant to the 2018 American College of Physicians position paper on achieving gender equity in physician compensation and career advancement (1), the Board of Regents of the American College of Physicians voted on 4 December 2024 to amend the organization's policy on paid family and medical leave. The American College of Physicians now supports universal access to family and medical leave policies that provide ideally 12 weeks, but at a minimum 6 weeks, of paid leave and calls for legislative or regulatory action at the federal, state, or local level to advance this goal. The American …
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Authors: Breelyn A. Wilky, Gary K. Schwartz, Michael S. Gordon, Anthony B. El-Khoueiry, Andrea J. Bullock, Brian Henick, Mark Agulnik, Arun Singh, Daruka Mahadevan, Justin Stebbing, Chloe Delepine, Dhan Chand, Manushak Avagyan, Wei Wu, Benny Johnson, Joseph E. Grossman, Steven O'Day, Jonathan C. Trent, Robin L. Jones, Apostolia M. Tsimberidou
Journal: Journal of Clinical Oncology (2025)

PURPOSE Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in advanced sarcomas. METHODS BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years. The primary end point was to determine dose-limiting toxicities during the dose-escalation period. Secondary end points include objective response rate (ORR), duration of response (DOR), disease control rate, and progression-free survival (PFS) by RECIST 1.1. Exploratory end points include assessing patient biomarkers including tumor mutational burden, cytokines, and PD-L1 expression. RESULTS Overall, 64 patients with sarcoma were treated; all were evaluable for safety and 52 for efficacy. The most common treatment-related adverse event (TRAE) was diarrhea/colitis occurring in 35.9% of patients, with grade 3 in 6.3% of patients. No grade 4 or 5 TRAEs were reported. For all evaluable patients, ORR was 19.2% (95% CI, 9.6 to 32.5), and 27.8% (95% CI, 9.7 to 53.5) for evaluable patients with angiosarcoma (n = 18); 33.3% in visceral and 22.2% in cutaneous subtypes. Median PFS for evaluable patients was 4.4 months (95% CI, 2.8 to 6.1), with a 6-month PFS rate of 36% (95% CI, 22 to 50) and a median DOR of 21.7 months (95% CI, 1.9 to not reached). CONCLUSION The combination of BOT/BAL demonstrated promising efficacy and safety in a large cohort of heavily pretreated sarcoma patients. This encouraging activity warrants further investigation (ClinicalTrials.gov identifier: NCT03860272 ).
Author Correction: Endocisternal interfaces for minimally invasive neural stimulation and recording of the brain and spinal cord
Authors: Joshua C. Chen, Abdeali Dhuliyawalla, Robert Garcia, Ariadna Robledo, Joshua E. Woods, Fatima Alrashdan, Sean O’Leary, Adam Husain, Anthony Price, Scott Crosby, Michelle M. Felicella, Ajay K. Wakhloo, Patrick Karas, Nicole Provenza, Wayne Goodman, Sameer A. Sheth, Sunil A. Sheth, Jacob T. Robinson, Peter Kan
Journal: Nature Biomedical Engineering (2025)
Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation
Authors: Paresh P Kulkarni, Ravi Kumar Alluri, Matthew J Godwin, Gabriel L Forbes, Alona A Merkulova, Sylviane Lambert, Aatira Vijay, Maierdan Palihati, Suman Kundu, Young Jun Shim, Kevin N Kalonji, Alvin H. Schmaier, Michael Holinstat, SCOTT J CAMERON, Keith R McCrae
Journal: Blood (2025)
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response
Authors: Sravya Tumuluru, James K. Godfrey, Alan Cooper, Jovian Yu, Xiufen Chen, Brendan MacNabb, Girish Venkataraman, Yuanyuan Zha, Benedikt Pelzer, Joo Y. Song, Gerben Duns, Brian Sworder, Sandeep S Raj, Christopher R Bolen, Elicia Penuel, Ekaterina Postovalova, Nikita Kotlov, Aleksander Bagaev, Nathan H Fowler, Roni Shouval, Sonali M Smith, Ash A Alizadeh, Christian Steidl, Justin P. Kline
Journal: Blood (2025)